Novo Nordisk/$NVO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novo Nordisk

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ticker

$NVO
Sector

Primary listing

NYSE

Employees

78,387

Headquarters

Bagsvaerd, Denmark

Novo Nordisk Metrics

BasicAdvanced
$266B
15.32
$3.89
0.27
$1.23
1.38%

What the Analysts think about Novo Nordisk

Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.

Bulls say / Bears say

Novo’s experimental next-generation obesity injection achieved up to 22% weight loss in early-stage trials, restoring investor optimism about its pipeline after previous setbacks. (Bloomberg)
The $2 billion agreement made in March with United Laboratories for a portfolio of multi-mechanism obesity drugs broadens Novo’s pipeline beyond semaglutide and could diversify its long-term growth prospects. (Bloomberg)
The FDA’s announcement in February that Ozempic and Wegovy supply issues were resolved highlights Novo Nordisk’s improved manufacturing capacity, lowering the risk of shortages and supporting stable market share. (Bloomberg)
In July, Novo Nordisk reduced its 2025 sales growth forecast to 8%–14% and cut its operating profit outlook to 10%–16% following weaker-than-expected U.S. sales of Wegovy and Ozempic, marking the second downward revision this year. (Reuters)
A recent Breakingviews analysis cautions that increasing competition from Roche, Pfizer, and more than 140 drugs in development could cut Novo's combined GLP-1 market share by half by 2030, putting its market dominance at risk. (Reuters Breakingviews)
Novo shares experienced a sharp drop in March after CagriSema trial results disappointed, casting doubt on the strength of its pipeline outside of semaglutide-based therapies. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Novo Nordisk Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novo Nordisk Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVO

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs